An Escherichia coli-based bioengineering strategy to study streptolysin S biosynthesis.

Group A Streptococcus pyogenes (GAS) is a leading human pathogen that produces a powerful cytolytic bacteriocin known as streptolysin S (SLS). We have developed a bioengineering strategy to successfully reconstitute SLS activity using heterologous expression in laboratory strains of Escherichia coli. Our E. coli-based heterologous expression system will allow more detailed studies into the biosynthesis of other bacteriocin compounds and the production of these natural products in much greater yield. Published by Elsevier Inc.